Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS | $2.6 | $2.1 | $2.0 | ($1.0) | $3.7 | $4.2 | $0.3 | $2.1 | $2.2 | $1.5 | $4.2 | $1.6 | $2.1 | $1.0 | $2.4 | $3.8 | $2.8 | $5.2 | $5.7 | $0.1 |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Merck & Co., Inc.'s last 12-month EPS is $4.8, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Merck & Co., Inc.'s EPS growth was 163.7%. The average annual EPS growth rates for Merck & Co., Inc. have been 20.0% over the past three years, 5.8% over the past five years.
Over the last year, Merck & Co., Inc.'s EPS growth was 163.7%, which is higher than industry growth of (0.2%). It indicates that Merck & Co., Inc.'s EPS growth is Good.